OptimizeRx Lowers FY2026 Sales Guidance from $109.000M-$114.000M to $95.000M-$100.000M vs $111.438M Est

Benzinga Newsdesk www.benzinga.com Negative 95.9%

Neg 95.9% Neu 0% Pos 0%

OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $109.000 million-$114.000 million to $95.000 million-$100.000 million vs $111.438 million estimate.